Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience

Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C–lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.